ClinVar Miner

Submissions for variant NM_003722.5(TP63):c.694A>G (p.Lys232Glu)

dbSNP: rs1560274243
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000695736 SCV000824251 pathogenic TP63-Related Spectrum Disorders 2021-01-02 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change does not affect the transactivation ability of TP63 for its target gene retSDR1 (PMID: 20543567), however the clinical significance of this finding is unknown. This variant has been reported to segregate with ectrodactyly, ectodermal dysplasia, cleft lip/palate (EEC) syndrome in several families (PMID: 22574117, 11462173) . This variant is also known as c.577A>G (p.Lys193Glu) in the literature This variant is not present in population databases (ExAC no frequency). This sequence change replaces lysine with glutamic acid at codon 232 of the TP63 protein (p.Lys232Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.